Tocilizumab in the treatment of adult rheumatoid arthritis | Immunotherapy
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases - Tanaka - 2011 - FEBS Letters - Wiley Online Library
Mechanism of action of tocilizumab in RA (bathtub theory). Notes: The... | Download Scientific Diagram
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia | SpringerLink
Actemra Shortage: What to Do If You Can't Access Tocilizumab
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Actemra | Uses, Safety Info & Comparison to Other RA Drugs
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases - Tanaka - 2011 - FEBS Letters - Wiley Online Library
Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review)
Tocilizumab-Atlizumab Overview - Creative Biolabs
Outlook of IL-6 signaling blockade for COVID-19 pneumonia | Inflammation and Regeneration | Full Text
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19 - ScienceDirect
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy | Nature Reviews Immunology
Figure 5 | The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases | SpringerLink
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond | Journal of Ophthalmic Inflammation and Infection | Full Text
Tocilizumab Raises GI Risks in Rheumatoid Arthritis | MedPage Today
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Clinical experience of IL-6 blockade in rheumatic diseases—Implications on IL-6 biology and disease pathogenesis - ScienceDirect
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Figure 1 | Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy
JCI - IL-6 polymorphisms: a useful genetic tool for inflammation research?
IJMS | Free Full-Text | Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence | HTML
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
